---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-099390"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2026-08-21T11:53:12+00:00"
generated_at: "2026-08-21T11:55:07.421160+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arbutus plans $230M Dutch auction tender offer at $5.00-$5.75/share

## Summary
- Tender offer to repurchase up to $230M of common shares at $5.00-$5.75/share, funded from cash on hand.
- Offer expected to commence ~Aug 24, 2026 and expire ~Sep 29, 2026; subject to Canadian/US exemptive relief.
- CEO cites March 2026 Moderna settlement and July 2026 initial payment as funding source for the buyback.
- J.P. Morgan Securities LLC is dealer-manager; Georgeson LLC and TSX Trust are info agent and depositary.
- Company will continue to enforce LNP patent rights against Pfizer and BioNTech alongside licensee Genevant.

## SEC filing metadata
- accession: 0001104659-26-099390
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2026-08-21T11:53:12+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000110465926099390/0001104659-26-099390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000110465926099390/tm2623751d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-099390
- JSON: https://secwatch.observer/filing/0001104659-26-099390.json
- Plain text: https://secwatch.observer/filing/0001104659-26-099390.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.